Trial Profile
An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Itacitinib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 27 Sep 2022 Status changed from active, no longer recruiting to completed.
- 08 Mar 2022 Planned End Date changed from 31 Dec 2022 to 27 Oct 2022.
- 08 Mar 2022 Planned primary completion date changed from 31 Dec 2022 to 27 Oct 2022.